NCT04779957View on ClinicalTrials.gov

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Kidney TransplantationGraft Failure
Interventions
DRUG

Tocilizumab

Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.

Trial Locations (1)

Unknown

RECRUITING

CHU Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER